Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Careers
  • Newsroom
Company Announcement
15 August 2022

Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
Company Announcement
12 August 2022

Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move to the Nasdaq Main Market in IcelandListing on the Main Market can increase...
Financial Reports
28 July 2022

Filing of Amendment to Preliminary Prospectus on Form F-1 with U.S. Securities and Exchange Commission

On 27 July 2022, Alvotech filed an amendment to the Registration Statement on Form F-1 (the “Preliminary Prospectus”), previously filed on July 14 2022, with the U.S. Securities and Exchange Commission (the “SEC”). This amended registration statement is attached as a PDF.
Financial Reports
22 July 2022

Filing of Preliminary Prospectus on Form F-1 with U.S. Securities and Exchange Commission

On 22 July 2022, Alvotech filed a Registration Statement on Form F-1 (the “Preliminary Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”). This registration statement is attached as a PDF.
Company Announcement
20 July 2022

Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...
Financial Reports
15 July 2022

Filing of Preliminary Prospectus on Form F-1 with U.S. Securities and Exchange Commission

On 14 July 2022, Alvotech filed a Registration Statement on Form F-1 (the “Preliminary Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”). This registration statement is attached as a PDF.
Company Announcement
14 July 2022

Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company

Four new members enhance independence and diversity of Board of Directors Alvotech (NASDAQ and First North Growth Market: ALVO), a global biotech company specialized in the development and...
Managers’ Transactions
13 July 2022

Transactions of Managers and Closely Associated Persons

Company Announcement
13 July 2022

Aztiq and Alvogen subscribe to shares in Alvotech at listing price of $10 per share

Alvogen Lux Holdings S.à r.l. (“Alvogen”) and Aztiq Pharma Partners S.à r.l. (“Aztiq”) have each subscribed to 2,500,000 newly issued shares of Alvotech (the “Company”) for a price of $10 per share. The 5,000,000 shares were issued pursuant to the terms of settlement agreements between the Company a
Company Announcement
07 July 2022

Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®  

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studiesEylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion...
1…2728…33
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.